Between USA and EU there is an ocean
 

I cannot understand while there is such a gap between USA and EU about Avastin and Ixempra. The first is approved in EU for advanced breast cancer while has been just withdrawn in the USA. The second is used to tread metastatic breast cancer in USA since 2007 but in EU was never approved.

I cannot understand this different approach, it's so incosistent, and makes me angry because thousands of women with MBC running out of option from both side of the atlantic ocean are deprived of one treatment option.

Switzerland seems to be an exception, because both the drugs are approved.

This makes me wonder, is it a matter of safety (as the authorities claim) or it is just a matter of economicity? I mean, approving one drug like avastin or ixempra always put an huge burden on the health system, thus better not include too many drugs.

Sorry, just wondering.

kykeon